Source comparison
Quickcomparison
Dose Range LL-37 0.5–1.6 mg/mL (topical) Thymosin Alpha-1 1.6–3.2 mg Frequency Once daily Twice weekly Administration Topical application (wound healing) Subcutaneous injection Cycle Length 12+ weeks 8-12 weeks Onset Speed Moderate (1-2 weeks) Evidence Level M
This comparison does not assign a generated winner or score.
- Dose Range
- LL-37
- 0.5–1.6 mg/mL (topical)
- Thymosin Alpha-1
- 1.6–3.2 mg
- Frequency
- Once daily
- Twice weekly
- Administration
- Topical application (wound healing)
- Subcutaneous injection
- Cycle Length
- 12+ weeks
- 8-12 weeks
- Onset Speed
- Moderate (1-2 weeks)
- Evidence Level
- Moderate human trials (Phase 1-2)
- Efficacy